Pharmgate Announces Agreement to Acquire the Assets of Pennfield Animal Health

Pharmgate Announces Agreement to Acquire the Assets of Pennfield Animal Health

October 16, 2014

RAMSEY N.J.--()--Pharmgate LLC is pleased to announce an agreement to acquire Pennfield Animal Health. This acquisition will establish Pharmgate as a key supplier of finished medicated feed additive and water soluble products to the United States, Canadian, Mexican and Latin American livestock and poultry markets. The acquisition is expected to be completed before the end of 2014.

Pharmgate will acquire the current operations in Omaha, Nebraska which includes office buildings, a manufacturing facility, warehouses and the entire manufacturing, laboratory, finance, customer service, sales and marketing workforce. This will significantly enhance Pharmgate's expanding product portfolio which now includes the in-feed and water soluble Pennchlor ®, Pennox® and combination products.

Colin Gray, Pharmgate's President, said, "The deal provides an opportunity for Pharmgate to fast track our objective of establishing a North American presence. After introducing Pharmgate's branded chlortetracycline in the Canadian and Latin American markets, the chance to acquire a well-established and reputable product line in the United States permitted a rapid and sizable growth opportunity. We are excited that this acquisition, along with the seasoned and expert workforce, will drive and streamline our development pipeline projects. The acquisition provides a strong base from which to continue our growth in the medicated feed additive and water soluble product sectors."

About Pharmgate

Pharmgate LLC is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds. The company has marketing or supply approvals for these products in most major markets throughout the world.

Pennchlor® and Pennox® are the registered trademarks of Pennfield Oil Company, Inc.

Contacts

Pharmgate LLC
Colin Gray +1-201-327-3800

 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…